DNLI:NSD-Denali Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 31.24

Change

0.00 (0.00)%

Market Cap

USD 3.84B

Volume

0.48M

Avg Analyst Target

USD 71.60 (+129.19%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


DNLI Stock Forecast & Price:
Based on the Denali Therapeutics Inc stock forecasts from 4 analysts, the average analyst target price for Denali Therapeutics Inc is USD 71.60 over the next 12 months. Denali Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Denali Therapeutics Inc is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, Denali Therapeutics Inc’s stock price was USD 31.24. Denali Therapeutics Inc’s stock price has changed by +1.59% over the past week, +27.77% over the past month and -59.43% over the last year.

About Denali Therapeutics Inc (DNLI:NSD)

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibit ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

N/A

USD73.48B 29.71 20.69
REGN Regeneron Pharmaceuticals Inc

N/A

USD65.40B 8.39 6.52
MRNA Moderna Inc

N/A

USD59.64B 4.20 2.94
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.28B 2.86 1.54
SGEN Seagen Inc

N/A

USD33.15B 55.02 -50.53
RPRX Royalty Pharma Plc

N/A

USD28.81B 29.89 16.26
GMAB Genmab AS

N/A

USD21.88B 64.29 5.76
ARGX argenx NV ADR

N/A

USD20.61B N/A -30.89
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing DNLI

Symbol Name Weight Mer Price(Change) Market Cap
XSU:CA iShares US Small Cap (CAD.. 0.00 % 0.36 %

+0.10 (+0.30%)

USD0.43B
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

N/A

USD0.85B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

N/A

USD6.27B
2B77:XETRA iShares Ageing Population.. 0.00 % 0.40 %

+0.02 (+0.34%)

USD0.84B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.00 % 0.30 %

+0.80 (+0.34%)

USD1.31B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.96% 69% D+ 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.96% 69% D+ 43% F
Trailing 12 Months  
Capital Gain -59.43% 57% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.43% 57% F 30% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 45.91% 81% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.91% 81% B- 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 96.79% 25% F 13% F
Risk Adjusted Return 47.43% 86% B 78% C+
Market Capitalization 3.84B 95% A 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 136.02 7% F 8% F
Price/Book Ratio 3.92 25% F 21% F
Price / Cash Flow Ratio -18.17 91% A- 82% B-
EV/EBITDA -9.59 93% A 85% B
Management Effectiveness  
Return on Equity -28.25% 80% B- 32% F
Return on Invested Capital -27.94% 77% C+ 28% F
Return on Assets -12.68% 83% B 28% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 14.68 7% F 4% F
Short Percent 9.48% 27% F 20% F
Beta 1.89 23% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector